BioSpace News Archive

RxSight, Inc., an ophthalmic medical device company, announced the appointment of three new members to its Board of Directors effective as of the closing of the Company’s initial public offering on August 3, 2021.

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the Investigational New Drug (IND) approval of its Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib by China National Medical Products Administration (NMPA) for starting phase II clinical trial in primary immune thrombocytopenia (ITP) in China.

Rakuten Medical, Inc. today announced that it has appointed Nitin Nohria and Hiroshi Takasawa to the company’s board of directors.

Intercept Pharmaceuticals, Inc. announced that it has entered into privately negotiated agreements with certain of the holders of its existing 3.25% Convertible Senior Notes due 2023 and 2.00% Convertible Senior Notes due 2026 to exchange an aggregate of $306.5 million principal amount of 2023 Notes and an aggregate of $114.7 million principal amount of 2026 Notes for a newly issued series of Convertible Senior Secured Notes due 2026.

ImmVira announced that it has initiated its lead oncolytic virus therapy program MVR-T3011 IV (also known as T3011). The first patient has been dosed, receiving MVR-T3011 intravenous (IV) administration in the U.S. on August 10, 2021.